Dr Campbell, UK, has made a summary of recent investigations and studies on VIT D and its effect on PCa specifically and cancer generally. Of import is his discussiono on the finding on PCa and African Americans; they have a genomic risk factor that leads to more aggressive PCa, BUT respond quickly to VIT D supplementation...
Of significant note as well is that for every 8 ng/ml increase in the circulating level of VIT D you have in your blood you get a 9% decrease in HR or hazard ratio for all cause mortality and PCaSM (prostate cancer specific mortality); see MIN 6:00 in the podcast. So the normal level of 40 ng/ml could be bumped up, as I have done, to 60 ng/ml via supplementation and according to these studies give a 18%+ reduction in risk…something to consider. The podcast goes into other details as well.
(PS: Went back and checked my VIT D levels and my body weight the year before I was diagnosed…VIT D was 14.4 ng/ml and I weighed 268 Lbs, now 180…wonder if that made a difference as I have a very aggressive cancer cell type, i.e., Decipher 0.97).
Sadly, the podcast doubles down on BMI; being overweight significantly increases your risk of developing metastatic (MET) or fatal PCa and negates the effects of VIT D supplementation. In fact going from a BMI of 25 to 30 increases your risk by 70%, p=0.03 (3 percent chance that the outcome is false).
Podcast:
Circulating vitamin D level and mortality in prostate cancer patients: a dose–response meta-analysis…
Publication: Circulating vitamin D level and mortality in prostate cancer patients - pubmed.ncbi.nlm.nih.gov/303...
Results:
Higher vitamin D level could reduce the risk of death among prostate cancer patients.
Association of circulating 25-hydroxyvitamin D level with prognosis of prostate cancer.
NIH conducted a dose-response meta-analysis.
• Seven eligible cohort studies, n = 7, 808 patients
• The summary HR (hazard ratio) of prostate cancer-specific mortality correlated with an increment of every 20 nmol/L in circulating vitamin D, (20 nmol/L = 8 ng/ml) HR = 0.91, (P = .002).
• Every 20 nmol/L increment (8 ng/ml) in 25-hydroxyvitamin D level was associated with a 9% lower risk of, all-cause mortality, and prostate cancer-specific mortality.
• Pooled HRs were stable and not obviously changed by any single study.
• No evidence of publications bias was observed.
• This meta-analysis suggested that higher 25-hydroxyvitamin D level was associated with a reduction of mortality in prostate cancer patients, and vitamin D is an important protective factor in the progression and prognosis of prostate cancer.
• Risk estimates with 95% CI (confidence intervals) for the association between 25(OH)D and prostate cancer-specific mortality.
Mechanism
• Vit D, could cause cell cycle arrest, and induce apoptosis, inhibiting cell proliferation in several prostate cancer cell lines.
• Protection from prostate epithelial cell lines from oxidative stress also provided.
Will supplements help?
Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial
• VITAL is a randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial of vitamin D3 (cholecalciferol, 2000 IU/d) and marine omega-3 fatty acids (1 g/d).
• 25 871 randomized VITAL participants (51% female)
• When stratified by BMI, there was a significant reduction for the vitamin D arm in incident metastatic or fatal cancer among those with normal BMI (BMI<25: HR, 0.62 [95% CI, 0.45-0.86])
• …but not among those with overweight or obesity (BMI 25-<30: HR, 0.89 [95% CI, 0.68-1.17]; BMI≥30: HR, 1.05 [95% CI, 0.74-1.49]) (P = .03 for interaction by BMI).
Publication - Effect of Vitamin D3 Supplements on Development of Advanced Cancer Stratified by BMI; pubmed.ncbi.nlm.nih.gov/332...
4,000 units (100 micrograms) per day dose; 24 of 44 subjects (55%) showed a decrease in the number of positive cores or decrease in Gleason score.
Prostate cancer in black Americans
African American (AA) prostate cancer associates with vitamin D3 deficiency, but vitamin D receptor (VDR) genomic actions have not been investigated in this context.
• We undertook VDR proteogenomic analyses in European American (EA) and AA prostate cell lines and four clinical cohorts.
• Major VDR functions were significantly corrupted in the isogenic AA RC43T Gene in prostate cancer cells, and significantly distinct from EA cell models.
• Strikingly, only in AA patients with prostate cancer, the genes bound by VDR and/or associated with 1α,25(OH)2D3-dependent open chromatin;
o (i) predicted progression from high-grade prostatic intraepithelial neoplasia to prostate cancer;
o (ii) responded to vitamin D3 supplementation in prostate cancer tumors;
o (iii) differentially responded to 25(OH)D3 serum levels.
• VDR transcriptional control is most potent in AA prostate cells and distorted through a BAZ1A-dependent control of VDR function.
Publication: African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1A Gene - aacrjournals.org/cancerresc...
Cancer prevention
Publication: NIH National Cancer Institute; Vitamin D and Cancer - cancer.gov/about-cancer/cau...
Numerous epidemiologic studies have shown that higher intake or blood levels of vitamin D are associated with a reduced risk of colorectal cancer
Author; Dr. John Campbell @Campbellteaching : YouTube 2.82M subscribers
